89BIO (ETNB) Stock Price, News & Analysis

Company Overview

89bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for metabolic and fibrotic diseases. The company’s lead candidate, pegozafermin, is a long-acting, pegylated analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of metabolic dysfunction, including liver fat accumulation, lipid abnormalities and inflammation. In addition to pegozafermin, 89bio is advancing a pipeline of next-generation FGF21-based molecules and receptor agonists aimed at treating a range of conditions linked to metabolic health.

Since its founding in 2018, 89bio has initiated multiple Phase 2 clinical trials evaluating pegozafermin in nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and other disorders characterized by insulin resistance and liver fibrosis. Early-stage studies have demonstrated improvements in key biomarkers such as liver fat content, triglyceride levels and markers of liver injury. The company’s strategic focus on a biology-driven approach supports potential expansion into complementary indications, including cardiovascular disease and chronic kidney disease in patients with metabolic syndrome.

Based in South San Francisco, California, 89bio serves patients worldwide through its clinical partnerships and global trial network. The company was founded by a team of biotechnology veterans and academic scientists to translate foundational insights in hormone biology into practical therapies. Under the leadership of CEO and President Farhad Gen, Ph.D., 89bio has assembled a management team with deep experience in drug development, regulatory affairs and commercial strategy. The company is backed by leading life science investors and collaborates with research institutions to accelerate its pipeline toward regulatory milestones and potential commercialization.

Key Stats

• Today's Range: $10.84 to $11.41
• 50-Day Range: $7.64 to $11.00
• 52-Week Range: $4.16 to $11.84
• Volume: 1.31 million shs
• Average Volume: 1.53 million shs
• Market Capitalization: $1.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.43
• Consensus Rating: Buy

89BIO Stock Analysis - MarketRank™

89BIO scored higher than 42% of companies evaluated by MarketBeat, and ranked 680th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

89BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

89BIO has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 89BIO are expected to grow in the coming year, from ($3.19) to ($2.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 89BIO is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 89BIO is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

89BIO has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.13% of the float of 89BIO has been sold short.

Short Interest Ratio / Days to Cover

89BIO has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in 89BIO has recently increased by 13.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

89BIO does not currently pay a dividend.

Dividend Growth

89BIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.13% of the float of 89BIO has been sold short.

Short Interest Ratio / Days to Cover

89BIO has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in 89BIO has recently increased by 13.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.90

News Sentiment

89BIO has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for 89BIO this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for ETNB on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added 89BIO to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 89BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91,208.00 in company stock.

Percentage Held by Insiders

Only 2.80% of the stock of 89BIO is held by insiders.

ETNB Stock Analysis - Frequently Asked Questions

How have ETNB shares performed this year?

89BIO's stock was trading at $7.82 at the beginning of the year. Since then, ETNB stock has increased by 42.2% and is now trading at $11.12.

How were 89BIO's earnings last quarter?

89BIO (NASDAQ:ETNB) announced its quarterly earnings results on Thursday, May, 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.01.

When did 89BIO IPO?

89BIO (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89BIO's major shareholders?

89BIO's top institutional shareholders include Assenagon Asset Management S.A. (1.49%) and Harbor Capital Advisors Inc. (0.15%). Insiders that own company stock include Ra Capital Management, LP, Rohan Palekar, Quoc Le-Nguyen, Michael R Hayden, Ryan Martins, Charles Mcwherter, Edward Morrow Atkinson III and Kathleen Laporte.
View institutional ownership trends.

How do I buy shares of 89BIO?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 89BIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 89BIO investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ETNB
• CIK: 1785173
• Web: www.89bio.com
• Phone: 415-432-9270
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for 89BIO: $26.43
• High Price Target: $49.00
• Low Price Target: $11.00
• Potential Upside/Downside: +135.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$367.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.44%
• Return on Assets: -70.17%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 18.03
• Quick Ratio: 18.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.34 per share
• Price / Book: 3.36

Miscellaneous

• Outstanding Shares: 145,980,000
• Free Float: 141,896,000
• Market Cap: $1.64 billion
• Optionable: Optionable
• Beta: 1.28